TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 2 Diabetes Mellitus with inadequate glycemic control~Exclusion Criteria:~* Patients with Type 1 Diabetes Mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 10 mg tablet daily for 54 weeks
- Placebo/ Pioglitazone (Type: PLACEBO_COMPARATOR): Placebo tablet daily for 24 weeks followed by Pioglitazone tablet daily for 30 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are male or female aged 18-55 years at the time of signing the informed consent form.~Exclusion Criteria:~* Have been treated previously with monoclonal antibody agent including any tumour necrosis factor inhibitor except SB4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SB4 (Type: EXPERIMENTAL): SB4 (etanercept) 50 mg/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females over 18 years of age~* 2-50 warts in the anogenital region.~* Female patients of child-bearing potential had to be willing to use a non-barrier method of contraception at entry and for the duration of the study.~* all patients had to be willing to use barrier protection for the duration of the study.~* All patients had to be able to comply with the requirements of the protocol and be likely to return for follow-up visits and had to be contactable for the duration of the study.~Exclusion Criteria:~* Patients with clinically relevant abnormal haematology or biochemistry results (determined from the sample taken at Visit 1).~* Patients who had used an active therapy for anogenital warts within 2 weeks of randomisation to study drug, i.e. Visit 2.~* Patients who had used any local supportive medication, including topical corticosteroids or beta-interferon, within 2 weeks of study entry.~* Patients who had used medication known to adversely affect their haematology profile, including local anaesthetics (benzocaine, lidocaine, etc), nitrofurantoin, sulphonylureas and sulphonamides within 2 weeks of study entry. \[Word 'adversely' added by Protocol Amendment 2, 7 May 2002.\]~* Patients with abnormal anogenital skin, such as eczema, or skin that had not healed following surgery (cryosurgery, laser ablation or similar).~* Patients who were known to have a concomitant sexually transmitted disease that inhibited accurate assessment of their warts.~* Patients who required treatment other than surgery or laser for internal warts.~* Male patients with intra-urethral warts \[deleted by Protocol Amendment 2, 7 May 2002\].~* Patients with diabetes (Type I or Type II diabetes).~* Patients who were known to be HIV-positive.~* Patients who were known to be immunosuppressed and/or using immunosuppressive therapies.~* Patients known to abuse alcohol and/or drugs or with a history of chronic alcohol or drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo 0% nitrite cream and placebo 0% citric acid cream
- Topical NO Dose A (Type: ACTIVE_COMPARATOR): 3% sodium nitrite + 4.5% citric acid twice daily
- Topical NO Dose B (Type: ACTIVE_COMPARATOR): 6% sodium nitrite + 9% citric acid once daily
- Topical NO Dose C (Type: ACTIVE_COMPARATOR): 6% sodium nitrite + 9% citric acid twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health~* Written informed consent provided by or for the subject~* Aboriginal ethnicity (First Nations, Metis or Inuit)~* Adults 20-59 years of age~* Children 6-35 months of age~Exclusion Criteria:~* Allergies to eggs, thimerosal or gentamicin sulphate~* Life-threatening reaction to previous Flu vaccine~* Bleeding disorder~* Pregnancy~* Receipt of blood or blood products in past 3 months~* Compromised immune system~* Chronic illness~* Previous lab-confirmed H1N1/2009 infection

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): Adults: One doses of H1N12009 vaccine
- 2 (Type: OTHER): Children: Two doses of H1N12009 vaccine given 3 weeks apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrated Treatment for Posttraumatic Stress Disorder and Substance Abuse in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-25 years old~* meets diagnostic criteria for substance use disorder~* meets diagnostic criteria for full or subthreshold posttraumatic stress disorder~* currently able to provide a urine drug screen that is negative for cocaine, prescription opiates, and non-prescribed methadone or provided this type of screen in the past 60 days~* speaks English~Exclusion Criteria:~* significant cognitive impairment or serious uncontrolled psychiatric problem (other than posttraumatic stress disorder)~* in recovery from pathological gambling or current pathological gambling diagnosis~* in a current domestic violence relationship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Prolonged Exposure + Contingency Management (Type: EXPERIMENTAL): Standard services plus Prolonged Exposure and Contingency Management
- Standard Care (Type: ACTIVE_COMPARATOR): Standard substance abuse treatment services

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65 or older~* High concerns or high risk of fall~* Ambulatory~Exclusion Criteria:~* Presence of an active wound infection on either of the foot and ankle~* Use of medication or a medical condition that may have unstable (fluctuate over time) or temporary (less than one month) impact on gait and balance~* Acute fractures on the foot~* Participant of an interventional study within the last 30 days~* Non-ambulatory or unable to stand without help or walk a distance of at least 1.8 m (\~six feet) without assistance~* Major foot amputation~* Unable or unwilling to participate in all procedures

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MBB AFO Group (Type: EXPERIMENTAL): This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
- No MBB AFO Group (Type: ACTIVE_COMPARATOR): This group will be provided with a pair of New Balance 813 shoes for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Randomized in the parent study, PCYC-1115-CA~2. Informed consent for Study PCYC-1116-CA~3. Independent review committee (IRC)-confirmed disease progression (PD) in the parent study PCYC-1115-CA or closure of the parent study~Exclusion Criteria:~1. Disease progression involving the central nervous system (CNS) or transformation to another histology~2. Intervening chemotherapy, immunotherapy, or investigational agent specifically to treat CLL if administered before date of IRC confirmed progressive disease~3. In the 4 weeks before dosing: radiation therapy, major surgery, or receipt of an investigational drug~4. Requirement for treatment with a strong CYP3A inhibitor~5. Uncontrolled systemic infection or requirement for IV antibiotics~6. Noncompliance on the parent study(PCYC-1115-CA)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorambucil (Type: EXPERIMENTAL): Participants who received chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) Days 1 and 15 of 28-day cycle up to 12 cycles in Study 1115. In Study 1116, participants had the option to crossover to next-line ibrutinib 420 mg/day after disease progression (PD).
- Ibrutinib (Type: EXPERIMENTAL): Participants who received ibrutinib 420 mg daily in Study 1115 received ibrutinib orally once daily. Participants continuing in first-line ibrutinib therapy entered Study 1116 at the ibrutinib dose tolerated in Study 1115.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion criteria:~  1. Patients scheduled for left heart catheterization and undergoing PCI~ 2. Age 18-75 years~ 3. On aspirin (81mg) or aspirin (81mg) and clopidogrel (75mg/day)~ 4. Presence of at least one 2C19 LOF allele~* Exclusion criteria:~  1. Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel~ 2. Age \>75 years~ 3. Weight \<60kg~ 4. Considered at high risk for bleeding~ 5. History of ischemic or hemorrhagic stroke or transient ischemic attack~ 6. Known severe hepatic dysfunction~ 7. On treatment with oral anticoagulant therapy (Vitamin K antagonists, dabigatran, apixaban, rivaroxaban)~ 8. Use of glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)~ 9. Blood dyscrasia or bleeding diathesis~ 10. Platelet count \<80x106/mL~ 11. Hemoglobin \<10 g/dL.~ 12. Active bleeding or hemodynamic instability~ 13. Creatinine Clearance \<30 mL/minute~ 14. Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~ 15. Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~ 16. Pregnant females\* \*Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: ACTIVE_COMPARATOR): The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
- Prasugrel (Type: EXPERIMENTAL): The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 15-65~2. Ph-(BCR-ABL1 negative)B-ALL was diagnosed according to WHO diagnostic criteria~3. Newly diagnosed patients without prior induction therapy (except hydroxyurea and glucocorticoids ≦5 days)~4. ECOG score 0-3~5. Liver function: total bilirubin ≦ 3 times the upper limit of normal; Alanine aminotransferase ≦ 3 times upper limit of normal motion; Aspartate aminotransferase ≦ 3 times upper limit of normal motion; (except considering leukemia infiltration)~6. Renal function: endogenous creatinine clearance ≧30ml/min~7. Patients must be able to understand and willing to participate in the study and must sign the informed consent form.~Exclusion Criteria:~1. Ph+ (BCR-ABL1 positive) ALL and known ABL class Ph-Like ALL~2. T cells ALL~3. Mature B-cell leukemia/lymphoma, B-cell lymphoma, isolated extramedullary disease~4. Acute mixed-cell leukemia~5. Central nervous system leukemia~6. HIV infection~7. HBV-DNA or HCV-RNA positive~8. Patients with grade 2 or higher heart failure and other patients deemed inappropriate for inclusion by the investigator~9. Pregnant or breastfeeding patients~10. The study patient was refused enrollment

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- reduced-intensity chemotherapy followed by berintuzumab (Type: EXPERIMENTAL): Induction therapy was performed with reduced intensity chemotherapy (including 1 dose of Idarubicin 8 mg/m2, 1 dose of Vindesine 3 mg/m2, and 7 days of Dexamethasone 9 mg/m2/d) followed by 2 weeks of Blinatumomab (9 ug/d d8-14, 28 ug/d d15-21) immediately. Bone marrow evaluation was performed on day 22±2, and consolidation therapy was performed after achieving bone marrow remission (CR/CRh/CRi). If CR/CRh/CRi was not achieved in the first course of induction therapy, Blinatumomab (28ug/d×14d) should be continued and bone marrow evaluation should be evaluated again.~The regimen of consolidation therapy is recommended as multidrug combination chemotherapy (including high-dose Methotrexate or Cytarabine combined with Asparaginase) or alternating with Blinatumomab (28 ug/d×28d). If Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) is not performed, consolidation therapy needs at least 4 courses before 2 years maintenance therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of IPF based upon the Fleischner Society guidelines within 3 years from Screening (Part A) or based on ATS/ERS/JRS/ALAT 2018 guidelines within 5 years from Screening (Part B, C \& D)~* FVC % of predicted ≥45%~* DLco (hemoglobin-adjusted) ≥30%~* Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed, if on a stable dose for at least 3 months~Exclusion Criteria:~* Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDA~* Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio \<0.7 at Screening~* Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progression~* Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of Screening~* Smoking of any kind within 3 months of Screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Placebo
- PLN-74809 Dose Level 1 (Part A) (Type: EXPERIMENTAL): PLN-74809 Dose Level 1 (Part A) - 4 weeks
- PLN-74809 Dose Level 2 (Part A) (Type: EXPERIMENTAL): PLN-74809 Dose Level 2 (Part A) - 4 weeks
- PLN-74809 Dose Level 2 (Part B) (Type: EXPERIMENTAL): PLN-74809 Dose Level 2 (Part B) - 12 weeks
- PLN-74809 - Dose Level 3 (Part C) (Type: EXPERIMENTAL): PLN-74809 Dose Level 3 (Part C) - 12 weeks
- PLN-74809 - Dose Level 4 (Part C) (Type: EXPERIMENTAL): PLN-74809 Dose Level 4 (Part C) - 12 weeks
- PLN-74809 - Dose Level 5 (Part D) (Type: EXPERIMENTAL): PLN-74809 Dose Level 5 (Part D) - ≥ 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipid Efficacy Study (0524B-022)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 to 85 years of age with primary hypercholesterolemia or mixed hyperlipidemia~* LDL-C between 130 and 190 mg/L (Category I) and 130 and 160 mg/L (Category II) and triglycerides \</= 350 mg/dL.~Exclusion Criteria:~* A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study~* Patients with \<80% compliance~* Patients with certain medical conditions~* Patients taking certain concomitant medications and/or with unstable doses of medications~* Or those with a history of CHD/CHD equivalent or diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol.~* A male or female, who was primed with meningococcal vaccine 134612 or Mencevax™ ACWY in the primary vaccination study 18 months before the first persistence assessment and who completed that study.~* Written informed consent obtained from the subject/ from the parent or guardians of the subject.~* Written informed assent obtained from the subject, as applicable, at the time of study entry.~Exclusion Criteria:~• Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine since the last visit of the primary vaccination study.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects previously primed with meningococcal vaccine 134612.
- Group B (Type: ACTIVE_COMPARATOR): Subjects previously primed with Mencevax™ ACWY.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with stable, moderate to severe hidradenitis suppurativa~* Negative Chest X-ray and PPD test at Screening. If participant has had a past ulcerative reaction to PPD placement and/or chest X-ray consistent with prior tuberculosis exposure, the participant must initiate, or have documented completion of, a course of anti-tuberculosis therapy.~* Ability to administer subcutaneous injections~* General good health otherwise~Exclusion Criteria:~* Prior anti-TNF therapy~* Unstable antibiotic therapy for HS~* Required medication washouts for other HS treatments~* Prior exposure to Tysabri® (natalizumab);~* Recent infection requiring treatment~* Significant medical events or conditions that may put patients at risk for participation~* Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;~* History of cancer, except successfully treated skin cancer~* Recent history of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab 40 mg qwk (Type: EXPERIMENTAL): Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
- Adalimumab 40 mg eow (Type: EXPERIMENTAL): Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete